PATH
$44.32
Uipath Inc Cl A
$1.05
2.43%
PATH
Earnings Whisper ®
($0.01)
3rd Quarter October 2021
Consensus:  ($0.04)
Revenue:  $208.82 Mil
Wednesday
Dec 8
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PATH reports earnings?
Beat
Meet
Miss

Where is PATH's stock price going from here?
Up
Flat
Down
Stock chart of PATH
Analysts
Summary of analysts' recommendations for PATH
Score
Grade
Pivots
Resistance
$49.02
$47.16
$45.74

$43.88

Support
$42.46
$40.60
$39.18
Tweet
Growth
Description
NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company's product candidate, Zelrix is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan through the skin in a controlled manner using its proprietary SmartRelief technology. NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company is headquartered in Conshohocken, Pennsylvania.